The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

GATC brought together a broad coalition of researchers and executives in cell and gene therapy, gene editing, drug discovery and AI as well as patients and advocates.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Ovid Therapeutics announced it will name its president and chief operating officer Meg Alexander as its new CEO – replacing Jeremy Levin, effective January 1, 2026. She will also join the board of ...

Fintel reports that on November 12, 2025, Citigroup maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...